C. Armon

发表

Chapter 7 Epidemiology of Amyotrophic Lateral Sclerosis/Motor Neuron Disease

C. Armon, 2003 .

Assessment: Transcranial Doppler ultrasonography: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology*

A. Alexandrov, D. Goodin, D. Newell, 2004, Neurology.

From clues to mechanisms

C. Armon, 2008, Neurology.

Linear estimates of rates of disease progression as predictors of survival in patients with ALS entering clinical trials 1 Presented in part at the 8th International Symposium on ALS/MND held in Glasgow, Scotland, November 3–5th, 1997. 1

C. Armon, D. Moses, Carmel Armon, 1998, Journal of the Neurological Sciences.

Predictors of Outcome of Epilepsy Surgery: Multivariate Analysis with Validation

A. Friedman, C. Armon, R. Radtke, 1996, Epilepsia.

Alzheimer's disease underlies some cases of complex partial status epilepticus.

C. Armon, G. Peterson, B. Liwnicz, 2000, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

CT-guided thrombolytic treatment of patients with wake-up strokes☆

S. Tal, C. Armon, A. Bartal, 2019, eNeurologicalSci.

Can we eliminate placebo in ALS clinical trials?

J. Murphy, C. Armon, M. Ross, 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis

G. Parry, M. Bromberg, J. Petajan, 1996, Neurology.

A placebo‐controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis

G. Parry, J. Petajan, Robert G. Miller, 1996 .

Assessment: Transcranial Doppler ultrasonography: [RETIRED]

A. Alexandrov, D. Goodin, D. Newell, 2004, Neurology.

Motor unit number estimates and quantitative muscle strength measurements of distal muscles in patients with amyotrophic lateral sclerosis

M. Brandstater, C. Armon, G. Peterson, 1997, Muscle & nerve.

Motor unit number estimate–based rates of progression of ALS predict patient survival

M. Brandstater, C. Armon, 1999, Muscle & nerve.

Effect of the 2013 AHA/ASA guidelines on TPA use in acute ischemic stroke at Assaf Harofeh Medical Center in Israel

S. Tal, O. Gonen, C. Armon, 2016, Journal of the Neurological Sciences.

Assessment: Prevention of post–lumbar puncture headaches

D. Goodin, E. Frohman, R. Evans, 2000, Neurology.

Hyperbaric treatment of cerebral air embolism sustained during an open-heart surgical procedure.

T. Orszulak, C. Deschamps, C. Armon, 1992, Mayo Clinic proceedings.

ALSUntangled No. 37: Inosine*

R. Conwit, S. Paganoni, P. Andersen, 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.

Stem cells in amyotrophic lateral sclerosis

S. Appel, C. Armon, 2016, Neurology.

A brief quality-of-life measure for ALS clinical trials based on a subset of items from the sickness impact profile

G. Parry, J. Petajan, R. Barohn, 1997, Journal of the Neurological Sciences.

Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS

J. Petajan, R. Barohn, C. Armon, 1996, Neurology.

Electrophysiological signs of arteriovenous malformations of the spinal cord.

J. Daube, C. Armon, 1989, Journal of neurology, neurosurgery, and psychiatry.

Evidence-based guideline update: Intraoperative spinal monitoring with somatosensory and transcranial electrical motor evoked potentials

R. Emerson, D. Goodin, M. Nuwer, 2012, Neurology.

evoked potentials : Report of the Therapeutics and Technology monitoring with somatosensory and transcranial electrical motor Evidence-based guideline update : Intraoperative spinal

Faan, R. Emerson, D. Goodin, 2012 .

Early antiepileptic drug reduction following anterior temporal lobectomy for medically intractable complex partial epilepsy

Craig T Griffin, C. Armon, G. Kaptain, 2004, Seizure.

Limitations of inferences from observational databases in amyotrophic lateral sclerosis: all that glitters is not gold

R. Guiloff, R. Bedlack, C. Armon, 2002, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

Subacute encephalomyelitis presenting as stiff‐person syndrome: Clinical, polygraphic, and pathologic correlations

J. Mclean, P. Westbrook, M. Rodríguez, 1996, Movement Disorders.

ALSUntangled 38: L-serine

R. Conwit, J. Licht, P. Andersen, 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.

ALSUntangled No. 14: Mototab

C. Armon, 2012, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

ALSUntangled 13: Bee Venom

C. Armon, 2011, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

ALS Untangled No. 20: The Deanna Protocol

R. Conwit, J. Licht, P. Andersen, 2013, Amyotrophic lateral sclerosis & frontotemporal degeneration.

ALSUntangled 15: Coconut Oil

R. Conwit, J. Licht, P. Andersen, 2012, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

ALSUntangled No. 36: Accilion

R. Conwit, J. Licht, P. Andersen, 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.

Clinical neurophysiologic studies in stiff-man syndrome: use of simultaneous video-electroencephalographic-surface electromyographic recording.

C. Armon, P. McManis, B. Westmoreland, 1990, Mayo Clinic proceedings.

Acquired nucleic acid changes may trigger sporadic amyotrophic lateral sclerosis

C. Armon, 2005, Muscle & nerve.

Amiodarone for atrial fibrillation.

C. Armon, 2007, The New England journal of medicine.

Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary

G. Gronseth, L. Harkless, M. Pignone, 2021, Neurology.

Addendum to assessment: Prevention of post–lumbar puncture headaches

R. Evans, C. Armon, 2005, Neurology.

Addendum to assessment: Prevention of post–lumbar puncture headaches

R. Evans, C. Armon, 2005, Neurology.

A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group.

R. Barohn, R. Miller, C. Armon, 1996, Annals of neurology.

The underestimation of familial ALS and counseling patients with sporadic ALS

C. Armon, 2014, Neurology.

SOD1 A4V familial ALS in North America

C. Armon, 2009, Neurology.

Environmental Risk Factors for Amyotrophic Lateral Sclerosis

C. Armon, 2001, Neuroepidemiology.

Reliability of maximal voluntary isometric contraction testing in a multicenter study of patients with amyotrophic lateral sclerosis

J. Petajan, Robert G. Miller, M. Mendoza, 1997, Muscle & nerve.

Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group.

G. Parry, M. Bromberg, J. Petajan, 1996, Neurology.

Electrophysiological features and prognosis of Guillain-Barré syndrome in Israel: A single-center's 20 years' experience

C. Armon, Y. Leonov, Gilad Kenan, 2020, Journal of the Neurological Sciences.

Occurrence of amyotrophic lateral sclerosis among Gulf War veterans

L. Wilkins, C. Armon, 2003, Neurology.

Occurrence of amyotrophic lateral sclerosis among Gulf War veterans

C. Armon, 2004, Neurology.

VA STUDY OF GULF WAR DESERVES FURTHER SCRUTINY

C. Armon, 2003 .

Using MUNE to make linear estimates of rate of progression in ALS1

C. Armon, 2003 .

Epidemiologic correlates of sporadic amyotrophic lateral sclerosis

L. Kurland, J. Daube, C. Armon, 1991, Neurology.

Comparing composite scores based on maximal voluntary isometric contraction and on semiquantitative manual motor testing in measuring limb strength in patients with ALS

C. Armon, E. Ponraj, 1996, Neurology.

ALSUntangled: Introducing The Table of Evidence

R. Conwit, J. Licht, P. Andersen, 2015, Amyotrophic lateral sclerosis & frontotemporal degeneration.

Peer recommendations on how to improve clinical research, and Conference wrap-up

M. Turner, A. Ludolph, Robert G. Miller, 2013, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.

Correspondence regarding: TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol 2010:69;918-29.

Robert G. Miller, C. Armon, 2011, Journal of neuropathology and experimental neurology.

Short‐ and long‐term outcome and predictors in an international cohort of patients with neuro‐COVID‐19

E. Moro, E. Beghi, C. Bassetti, 2022, European journal of neurology.

ALSUntangled #67: rituximab

Gary L. Pattee, J. Glass, M. Benatar, 2022, Amyotrophic lateral sclerosis & frontotemporal degeneration.

Tales of Pacific tangles

R. Friedland, C. Armon, 2007, Neurology.

Antecedent medical diseases in patients with amyotrophic lateral sclerosis. A population-based case-controlled study in Rochester, Minn, 1925 through 1987.

L. Kurland, D. W. Mulder, C. Armon, 1991, Archives of neurology.

Hyperbaric Treatment of Cerebral Air Embolism Sustained During an Open-Heart Surgical Procedure

T. Orszulak, C. Deschamps, C. Armon, 1991 .

Practice parameter: Utility of electrodiagnostic techniques in evaluating patients with suspected peroneal neuropathy: An evidence‐based review

Robert G. Miller, C. Marciniak, C. Armon, 2005, Muscle & nerve.

Assessment: Use of epidural steroid injections to treat radicular lumbosacral pain

C. Argoff, C. Armon, M. Backonja, 2007, Neurology.

Smoking may be considered an established risk factor for sporadic ALS

C. Armon, 2009, Neurology.

Excess incidence of ALS in young Gulf War veterans

C. Armon, 2004, Neurology.

From Snow to Hill to ALS: An epidemiological odyssey in search of ALS causation

C. Armon, 2018, Journal of the Neurological Sciences.

Accrued somatic mutations (nucleic acid changes) trigger ALS: 2005–2015 update

C. Armon, 2016, Muscle & nerve.

Evidence-based guideline update: Intraoperative spinal monitoring with somatosensory and transcranial electrical motor evoked potentials

R. Emerson, M. Nuwer, T. Yamada, 2012, Neurology.

ALS Untangled No. 17: “When ALS Is Lyme”

R. Conwit, J. Licht, P. Andersen, 2012, Amyotrophic Lateral Sclerosis.

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial

W. Bamlet, S. Subramony, J. Mandrekar, 2008, Neurology.

Toward earlier diagnosis of amyotrophic lateral sclerosis

R. Barohn, R. Miller, C. Armon, 1998, Neurology.

Reversible parkinsonism and cognitive impairment with chronic valproate use

J. Edinger, C. Armon, P. Miller, 1996, Neurology.

When is an apparent excess of neurologic cases epidemiologically significant?

L. Kurland, D. W. Mulder, C. Armon, 1991, Neurology.

Sensorineural hearing loss

C. Armon, S. Carwile, P. Miller, 1990, Neurology.

Effects of a combined transcranial magnetic stimulation (TMS) and cognitive training intervention in patients with Alzheimer's disease

Á. Pascual-Leone, M. Sabbagh, C. Sadowsky, 2019, Alzheimer's & Dementia.

Smoking is a cause of amyotrophic lateral sclerosis. High low‐density lipoprotein cholesterol levels? Unsure

C. Armon, 2019, Annals of neurology.

Comment: Inverse association for risk of ALS and risk of all cancers

C. Armon, 2016, Neurology.

ALSUntangled No. 16: Cannabis

R. Conwit, J. Licht, P. Andersen, 2012, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

Prior Stroke in PFO Patients Is Associated With Both PFO-Related and -Unrelated Factors

A. Luft, F. Eberli, D. Kent, 2020, Frontiers in Neurology.

Seizure onset from periventricular nodular heterotopias

A. Friedman, S. Kothare, C. Armon, 1998, Neurology.

Estimating the X chromosome-mediated risk for developing Alzheimer’s disease

C. Armon, R. Shorer, S. Wolfson, 2021, Journal of Neurology.

An Evidence-Based Medicine Approach to the Evaluation of the Role of Exogenous Risk Factors in Sporadic Amyotrophic Lateral Sclerosis

C. Armon, 2003, Neuroepidemiology.

False lateralization of scalp EEG seizure onset

Darrell V. Lewis, Rodney A. Radtke, C. Armon, 1993 .

Alzheimer’s Disease Underlies Some Cases of Complex Partial Status Epilepticus: Clinical, Radiologic, EEG, and Pathologic Correlations

C. Armon, G. Peterson, B. Liwnicz, 2000 .

Inhibitory simple partial (non-convulsive) status epilepticus after intracranial surgery

C. Armon, R. Radtke, A. Friedman, 2000, Journal of neurology, neurosurgery, and psychiatry.

A blow to the head trauma–ALS hypothesis

S. Albert, C. Armon, 2015, Neurology.

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III

A. Pestronk, B. Levin, R. Sufit, 2009, Annals of neurology.

Normal Sleep, Sleep Physiology, and Sleep Deprivation: General Principles

M. Russo, J. Cavazos, C. Armon, 2006 .

Sports and trauma in amyotrophic lateral sclerosis revisited

C. Armon, 2007, Journal of the Neurological Sciences.

ALSUntangled No. 26: Lunasin

R. Conwit, J. Licht, P. Andersen, 2014, Amyotrophic lateral sclerosis & frontotemporal degeneration.

CME Assessment : Transcranial Doppler ultrasonography Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology *

A. Alexandrov, D. Goodin, D. Newell, 2004 .

Comparative features and outcomes of major neurological complications of COVID‐19

E. Beghi, C. Bassetti, R. Helbok, 2022, European Journal of Neurology.

Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis

C. Armon, C Armon, D. Moses, 2000, Muscle & nerve.

Computerized databases for ALS incidence calculations: ready, steady, but don’t go yet

O. Hardiman, C. Armon, 2009, European Journal of Neurology.

Is the lithium-for-ALS genie back in the bottle?

C. Armon, 2010, Neurology.

How can physicians and their patients with ALS decide to use the newly-available treatments to slow disease progression?

C. Armon, 2000, Amyotrophic Lateral Sclerosis and other Motor Neuron Disorders.

Physicians should desist from aiding in executions.

C. Armon, 2008, Mayo Clinic proceedings.

Robotic Mediastinal Surgery in Patients with Suspected Thymic Neoplasms: First Israeli Experience.

C. Armon, M. Peer, S. Azzam, 2018, The Israel Medical Association journal : IMAJ.

The beginning of precision medicine in ALS?

O. Hardiman, C. Armon, 2017, Neurology.

Theme 1 Epidemiology and informatics

C. Armon, 2019, Amyotrophic lateral sclerosis & frontotemporal degeneration.

ALSUntangled #64: butyrates

S. Paganoni, J. Glass, M. Bromberg, 2022, Amyotrophic lateral sclerosis & frontotemporal degeneration.

ALSUntangled No. 34: GM604.

Gary L. Pattee, R. Conwit, J. Licht, 2016, Amyotrophic lateral sclerosis & frontotemporal degeneration.

Mechanical trauma as a risk factor in classic amyotrophic lateral sclerosis: Lack of epidemiologic evidence

Glenn E. Smith, L. Kurland, K. Radhakrishnan, 1992, Journal of the Neurological Sciences.

Is head trauma a risk factor for amyotrophic lateral sclerosis? An evidence based review

C. Armon, Lorene M. Nelson, L. Nelson, 2012, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

Validation of MRI biomarker of white matter degeneration for ALS clinical trials

C. Armon, H. Shinotoh, 2020, Neurology.

ALSUntangled No. 29: MitoQ

R. Conwit, J. Licht, P. Andersen, 2015, Amyotrophic lateral sclerosis & frontotemporal degeneration.

How frequently does classic amyotrophic lateral sclerosis develop in survivors of poliomyelitis?

J R Daube, L. Kurland, A. Windebank, 1990, Neurology.

Reasons for delayed treatment initiation in Guillain-Barre syndrome

C. Armon, Gilad Kenan, I. Kimiagar, 2022, Journal of the Neurological Sciences.

Polyneuropathy Quality Measurement Set

Lyell K. Jones, Amy Bennett, Anant M. Shenoy, 2021, Neurology.

Amyotrophic lateral sclerosis: A global threat with a possible difference in risk across ethnicities

G. Logroscino, C. Armon, 2007, Neurology.